Effective June 2022, Wiley will manage copyright & licensing requests for assessment tools by the American College of Rheumatology. These tools include ACR 20/50/70 and SLICC/ACR Damage Index, among others.

What does this mean for researchers? Researchers with non-commercial funding sources will still be able to use these assessment frameworks in their research with no licensing fee.

For commercially-funded research, a licensing fee will be in effect beginning June 2022. Commercial licensing supports the ongoing work of the ACR. Licensees will also benefit from validated translations, scoring guides, and other resources for the rigorous use of the criteria in research and clinical trials; these materials will be supported by our partner Mapi Research Trust.

More about the Clinical Outcome Assessments from ACR

ACR 20/50/70

•    used to measure disease activity in rheumatoid arthritis (RA) clinical trials
•    Developed in 1993
•    Learn more in eProvide

SLICC/ACR Damage Index

•    used to develop and perform an initial validation of a damage index for systemic lupus erythematosus (SLE)
•    Developed in 1996
•    Learn more in eProvide

Do you want to use ACR tools in your research? 

Commercially-funded research projects should contact the Wiley licensing team to request a license.

Academic researchers with non-commercial funding sources can request reuse rights at no cost through our partner Mapi Research Trust. Supplementary resources will soon be available from Mapi. Once they are available, academic researchers and individual practitioners without commercial funding will be able to find download instructions on eProvide.